N
32.63
1.23 (3.92%)
| 前收盘价格 | 31.40 |
| 收盘价格 | 31.55 |
| 成交量 | 1,217,629 |
| 平均成交量 (3个月) | 1,247,312 |
| 市值 | 3,814,576,896 |
| 价格/销量 (P/S) | 158.40 |
| 股市价格/股市净资产 (P/B) | 5.24 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业利益率 (TTM) | -2,314.47% |
| 稀释每股收益 (EPS TTM) | -1.84 |
| 季度收入增长率 (YOY) | 112.60% |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 19.98 |
| 营业现金流 (OCF TTM) | -140.43 M |
| 杠杆自由现金流 (LFCF TTM) | -99.00 M |
| 资产报酬率 (ROA TTM) | -18.15% |
| 股东权益报酬率 (ROE TTM) | -31.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NewAmsterdam Pharma Company N.V | 看跌 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.13 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.39% |
| 机构持股比例 | 111.32% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Mar 2026 | 7,306,566 |
| Duquesne Family Office Llc | 31 Mar 2026 | 3,070,146 |
| Westfield Capital Management Co Lp | 31 Mar 2026 | 2,202,913 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合